In each of the studies, the primary endpoint (proportion of patients with an iPTH ≤ 250 pg/ ml (≤ 26.5 pmol/ l)) was achieved by 41%, 46%, and 35% of patients receiving cinacalcet, compared with 4%, 7%, and 6% of patients receiving placebo.
Kõigis kolmes uuringus saavutati esmane lõppeesmärk (patsientide osakaal, kelle iPTH ≤250 pg/ ml (≤26, 5 pmol/ l)) tsinakaltseedi rühmas 41%, 46% ja 35% patsientidest, võrreldes platseeborühma patsientidega vastavalt 4%, 7%, and 6%.